Brand Intelligence Graph
Company Overview
About Infant Bacterial Therapeutics
Infant Bacterial Therapeutics (IBT) is a Swedish biopharma company developing Lactobacillus reuteri DSM17938 — a probiotic bacterial strain — as a regulated drug (live biotherapeutic product) to prevent necrotizing enterocolitis (NEC) in premature infants. NEC is a devastating gastrointestinal emergency affecting 1–7% of premature newborns, with 30% mortality and severe long-term outcomes in survivors. No approved preventive treatments exist, despite decades of evidence suggesting certain probiotic strains reduce NEC incidence.
Business Model & Competitive Advantage
IBT's approach treats a well-characterized probiotic strain as a pharmaceutical product with rigorous GMP manufacturing, safety testing, and clinical development — a regulatory path enabled by the FDA and EMA's live biotherapeutic framework. The company's Phase 3 PROPREMS-3 trial across 40+ neonatal intensive care units is among the largest neonatal probiotic trials ever conducted, with results expected in 2026.
Competitive Landscape 2025–2026
Founded in 2014 and listed on Nasdaq First North in Stockholm, IBT has partnerships with major neonatal nutrition companies and has raised significant funding to complete the pivotal trial. Regulatory approval would create the first FDA/EMA-approved preventive therapy for NEC, addressing a critical unmet need in neonatal intensive care.
Key Differentiators
Emerging Innovator
Infant Bacterial Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare Infant Bacterial Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Infant Bacterial Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Infant Bacterial Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Infant Bacterial Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →